Product Code: WK1000
CAS Number: 156101-08-5
Molecular: Weight 432.55 g/mol
Formula C25H36O6
Appearance: Solid
Erinacine A is one of a group of natural compounds known as cyathin diterpenoids, isolated from the mushroom Hericium erinaceus (commonly known as lion’s mane). Erinacines (A-K, P, Q, S, U) have gained significant attention in pharmacological research due to their potential therapeutic properties. Erinacine A, the primary representative of this group, has been isolated from cultured mycelia of Hericium erinaceus and is known to promote the synthesis of nerve growth factor (NGF) in vitro. This neurotrophic effect suggests its potential for use in neuroregenerative and neuroprotective therapies.
Beyond its impact on nerve growth, erinacine A is being studied for a range of other possible applications, including its role in supporting cognitive function, reducing inflammation, and promoting overall brain health. Such broad-spectrum benefits position erinacine A as a promising candidate for further research in neurological and age-related conditions.
Erinacine A is known for its potent anticancer, anti-inflammatory, and neuroprotective properties. It has been shown to induce cancer cell death by activating both the extrinsic and intrinsic apoptotic pathways. Additionally, Erinacine A inhibits the expression of inducible nitric oxide synthase (iNOS) and reduces the production of nitrotyrosine, which contributes to its anti-inflammatory and neuroprotective effects, particularly in the context of reducing ischemic brain damage. Studies have demonstrated that Erinacine A (30 μM, 3-24 h) can significantly activate apoptosis in DLD-1 colon cancer cells, while also reducing the expression of key anti-apoptotic proteins.
Erinacine A has demonstrated promising biological activity in various in-vitro studies. For instance, treatment of TSGH 9201 human gastric cancer cells with erinacine A (1-10 µM; 24 h) increased cytotoxicity and the generation of reactive oxygen species (ROS), while reducing cell invasiveness. This treatment also activated caspases and induced the expression of TRAIL, contributing to apoptotic cell death. The apoptotic effect of erinacine A was linked to the sustained phosphorylation of the FAK/AKT/p70S6K and PAK1 signaling pathways, alongside ROS generation.
Furthermore, erinacine A’s ability to induce apoptosis and suppress invasiveness may involve the differential expression of proteins such as 14-3-3 sigma (1433S) and microtubule-associated tumor suppressor candidate 2 (MTUS2). These findings suggest that erinacine A could trigger an apoptotic cascade in TSGH 9201 cells via the FAK/AKT/p70S6K/PAK1 pathway, providing insight into its potential anti-cancer mechanisms in human gastric cancer.
Please be aware that all products and information provided by FUNGOTECH are intended for informational purposes only. The compounds available for purchase are designed strictly for in-vitro studies, which involve research conducted outside of living organisms, in controlled laboratory environments using cells or tissues. These products are not classified as medicines or therapeutic agents and have not been evaluated or approved by the FDA for use in the prevention, treatment, or cure of any disease or medical condition. Importantly, the introduction of these products into humans or animals is prohibited by law. Researchers must adhere to legal and ethical guidelines to ensure compliance during in-vitro experimentation.
For research use only. Not for human or veterinary use. Attention: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Our products are intended for lab use only. For any other use, please contact us. Controlled product. We may require documentation to meet relevant regulations. We has not independently confirmed the accuracy of these methods. They are for reference only.
